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Objective: This is the ﬁrst randomized controlled trial with a 5-year follow-up comparing endovenous laser ablation
(EVLA) with high ligation and pin-stripping in patients with great saphenous vein (GSV) incompetence.
Methods: One hundred twenty-one consecutive patients (137 legs) with GSV incompetence were randomized to EVLA
(980 nm bare ﬁber) or high ligation and stripping using tumescent local anesthesia with light sedation. Mini-
phlebectomies were performed in all patients. The patients were examined with duplex scanning before treatment and
after 12 days, and then after 1, 3, and 6 months, and yearly thereafter for up to 5 years. The primary end point was open
reﬂuxing GSV. Secondary end points were recurrent varicose veins, frequency of reoperations, Venous Clinical Severity
Score, and quality of life scores (Aberdeen Varicose Vein Symptoms Severity Score and Short Form-36).
Results: In the EVLA and stripping group, nine (Kaplan-Meier [KM] estimate, 17.9%) and four (KM estimate, 10.1%) of
GSVs had open reﬂuxing segments of 5 cm or more (ns). Clinical recurrence was recorded in 24 (KM estimate, 46.6%)
and 25 (KM estimate, 54.6%), whereas reoperations were performed in 17 (KM estimate, 38.6%) and 15 (KM estimate,
37.7%) legs (ns). Venous Clinical Severity Score and Aberdeen Varicose Vein Symptoms Severity Score improved whereas
Medical Outcomes Study Short Form-36 quality of life score improved in several domains in both groups with no
difference between the groups.
Conclusions: Five-year follow-up of our randomized controlled trial comparing EVLA with open surgery in patients with
GSV incompetence did not show any signiﬁcant difference between the two groups in primary or secondary end points,
perhaps because of the small sample size. EVLA seems to be a valid alternative to open surgery. (J Vasc Surg 2013;58:421-6.)3In recent years, endovenous laser ablation (EVLA) of
the saphenous veins has become an established treatment
in patients with varicose veins and saphenous vein incompe-
tence. Numerous reports have demonstrated a high degree
of safety and efﬁcacy of EVLA with respect to ablation of
the incompetent saphenous vein, leading to improvement
in symptoms and quality of life (QOL).1 However, most
reports are short- or medium-term, and only one random-
ized trial with long-term follow-up to 5 years has been
published so far. The study compared EVLA with cryo-
stripping and showed no difference in efﬁcacy between
the two treatments.2 The present randomized trial was
initiated in 2005 and compared EVLA with high ligation
and pin stripping in patients with varicose veins and great
saphenous vein (GSV) incompetence. The short-term
results showed little difference in outcome with onlythe Danish Vein Centers, Åreknudeklinikken, and Surgical Center
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Medium-term results showed no difference in clinical or
ultrasound recurrences or QOL.4 The present publication
represents the 5-year follow-up and is the third publication
from the trial. It describes the outcome with regard to clin-
ical and ultrasound recurrence, number of reoperations,
Venous Clinical Severity Score (VCSS), and QOL.
METHODS
The study was conducted in two private surgical centers
that work under contract with the national health-care
insurance in Denmark. The primary end point was open
reﬂuxing GSV. The reason why closure rate was chosen
for primary end point was because, at the time of planning
the study, little was known about the difference between
EVLA and stripping regarding this variable and the clinical
consequence of recanalization. Secondary end points were
recurrent varicose veins, frequency of reoperations, VCSS,
and QOL. The details of the methodology have been previ-
ously described.3,4 In brief, consecutive patients with symp-
tomatic varicose veins and GSV incompetence, CEAP
C2-4EpAsPr, were randomized using sealed envelopes to
either surgery or EVLA. Exclusion criteria were duplication
of the saphenous trunk or an incompetent anterolateral
accessory great saphenous vein (AAGSV), small saphenous
or deep venous incompetence, previous deep vein throm-
bosis, arterial insufﬁciency, or a tortuous GSV rendering
the vein unsuitable for endovenous treatment, age <18
and >80 years, and pregnancy. All treatments and assess-
ments were performed by one of two vascular or general421
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disease. Bilateral treatment was permitted provided both
limbs received the same treatment during the same opera-
tion. Patients who had undergone previous high ligation
without attempted stripping and/or phlebectomies were
included in the trial.
All treatments were performed in a treatment room
under tumescent local anesthesia using a solution of 0.1%
lidocaine with adrenaline and bicarbonate. A light sedation
with midazolam and alfentanil or diazepam was adminis-
tered in most cases.
The surgical procedure was carried out through a
4-6 cm incision in the groin, with ﬂush division and liga-
tion of the GSV and division of all tributaries. The GSV
was then removed to just below the knee using a pin-
stripper.
The EVLA procedure was performed under duplex
guidance with a 980-nm diode laser using a bare-tip ﬁber
(Ceralas D 980; Biolitec, Bonn, Germany) in pulse mode
and 12-watt power. The GSV was cannulated just below
the knee, or at the lowest point of reﬂux on the thigh.
The laser ﬁber was advanced to 1-2 cm below the sapheno-
femoral junction and withdrawn during ablation. All vari-
cose veins were removed by miniphlebectomies during
the same procedure in both groups of patients. After the
treatment, the legs were wrapped in sterile absorbent
bandages and covered with a compressive cohesive
bandage (C0-plus; Smith & Nephew, London, UK). After
48 hours, the patients removed the bandage and were told
to wear a class 1 compressive stocking during the day for at
least 2 weeks. We did not monitor compliance regarding
the use of the stockings.
The patients attended follow-up at 12 days and then
after 1, 3, and 6 months and yearly thereafter for up to
5 years. The surgeon performed clinical and duplex ultra-
sound (DUS) examinations sitting in front of the standing
patient at all visits. Examination for reﬂux was performed
using manual compression of the calf with sudden release.
Reﬂux in the untreated part of the GSV was not recorded.
A Hawk or Flex-Focus ultrasound system 7-10 MHz (BK
Medical, Denmark) was used for the DUS examinations.
Reﬂux >0.5 seconds was considered pathologic. The track
of the treated GSV and the femoral and popliteal veins
were investigated with DUS for visibility, compressibility,
blood ﬂow, and reﬂux. The Aberdeen Varicose Vein Symp-
toms Severity Score (AVVSS), VCSS, and the Medical
Outcomes Study Short Form (SF-36) health-related
QOL score were completed by the patient and recorded
by a research nurse.5-7 We used the original version of
the VCSS as in the previous two reports from this study.3,4
This version has been validated as a useful clinical outcomes
tool. Consistency in using the same VCSS by the same
practitioners will ensure less variability.
Recurrent varicose veins were deﬁned as the presence
of varicose veins after treatment.8 In patients with such
varicose veins or signs of venous insufﬁciency (C3 or
higher) the source of reﬂux, if possible, would be identiﬁed
and categorized as reﬂux in the groin, the GSV, AAGSV,and perforators in the thigh and/or the calf.8 In patients
without recurrent varicose veins, presence of reﬂux, except
in the treated part of the GSV, was not recorded. Technical
success was considered achieved when the treated part of
the GSV was closed or absent. Treatment failure was
deﬁned as an open reﬂuxing segment of the treated GSV
section >5 cm in length.9 Legs that developed open reﬂux-
ing GSVs and/or recurrent varicose veins were removed
from further clinical follow-up at the time of discovery of
such end point but after completion of the VCSS, AVVS,
and SF-36. However, 5 years postoperatively, such
patients, in addition to those who had not attended
previous visits, were invited for a ﬁnal assessment. Addi-
tional procedures would require a referral from the
patient’s primary physician and would be performed in
the presence of symptoms or unpleasant appearance. Peri-
operative details and results of the 2-year follow-up have
been described in detail previously.3,4
Statistical methods. A priori sample size calculations
indicated that to detect a 15% difference in closed or absent
vein between the groups with a 5 and b 80, 60 legs would
be needed in each group. GSV status, clinical recurrence,
pattern of reﬂux, and reoperations were analyzed by
Kaplan-Meier statistics. VCSS, AVVSS, and SF-36 were
analyzed by ANCOVA models adjusted for their respective
baseline values. The level of signiﬁcance was set at 5%.RESULTS
A total of 121 consecutive patients (137 legs) were
randomized to surgery or EVLA. The number of patients
and legs treated and examined at follow-up is shown in
the Consort diagram (Fig 1). The number of patients
screened was high because everyone referred for varicose
veins treatment was considered for the trial. The screening
would therefore include any kind of suspected venous
disease. Baseline patient characteristics are shown in
Table I. The groups were comparable with regard to
patient characteristics and CEAP classiﬁcation of the
treated legs.
GSV data. The Kaplan-Meier plot of the open,
reﬂuxing GSVs are shown in Fig 2. Nine (Kaplan-Meier
[KM] estimate, 17.9%) and 4 (KM estimate, 10.1%) of
GSVs were recorded as having open and reﬂuxing
segments of 5 cm or more during the ﬁrst 5 years in the
EVLA and stripping group, respectively (P ¼ .2145). The
four open reﬂuxing GSVs in the stripping group represent
snapped veins whereas the nine open reﬂuxing veins in the
EVLA group represent recanalization.
Clinical recurrence and pattern of reﬂux. The
Kaplan-Meier plot of legs with recurrent varicose veins is
shown in Fig 3. Recurrent varicose veins were recorded in
24 (KM estimate, 46.6%) and 25 (KM estimate, 54.6%)
legs during the 5 years in the laser and stripping group,
respectively (P ¼ .7209). There were more legs with
incompetent thigh perforators in the surgery group and
more legs with incompetent reﬂuxing AAGSV in the EVLA
group, but the difference was not statistically signiﬁcant
Table I. Baseline patient characteristics
Characteristics Surgery EVLA
Median age, years (range) 54 (22-78) 53 (26-79)
Sex (F/M) 43/16 41/21
CEAP, No. (%)
C2 51 (86) 50 (81)
C3 5 (8) 3 (5)
C4 3 (5) 9 (15)
Previous high ligation, No. (%) 11 (16) 11 (16)
Phlebectomies, No. (%) 2 (2.9%) 3 (4.3%)
EVLA, Endovenous laser ablation.
Fig 1. Consort diagram. EVLA, Endovenous laser ablation.
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developed clinical recurrence.
Reoperations. The Kaplan-Meier plot of legs with
reoperations is shown in Fig 4. Seventeen (KM estimate,
38.6%) and 15 (KM estimate, 37.7%) legs were re-treated in
the laser and stripping group, respectively, during the 5-year
follow-up (P ¼ .9876). Most patients were treated with
ultrasound-guided foam sclerotherapy; some were com-
bined with phlebectomies, which is standard practice in our
clinics.
VCSS. The VCSS score improved signiﬁcantly in both
groups from 1 month (P < .0001), with no signiﬁcantdifference between the groups except at 1 month
(P ¼ .0478) (Fig 5). The improvement was present after
1 month and lasted throughout the 5 years. The mean
(SD) VCSS at the start of the study was 2.8 (1.7) and 2.4
(1.4) and was reduced to 0.4 (0.9) and 0.4 (0.7) at 5 years
in the EVLA and surgery group, respectively.
AVVSS. The AVVSS improved signiﬁcantly in both
groups from 3 months and onward (P < .0001) with no
difference between the groups at any point in time
(Fig 6). The mean (SD) AVVSS at the start of the study
was 18.3 (8.8) and 16.0 (6.3) and was reduced to 3.0 (5.3)
and 3.6 (4.1) at 5 years in the EVLA and stripping group,
respectively.
SF-36 scores. Statistically signiﬁcant improvements
compared with baseline were seen at some points in time
in the domains bodily pain, mental health, social function,
physical function, and vitality and in the mental component
summary and physical component summary at all time-
points in both groups (Table III).
DISCUSSION
More patients in the EVLA group showed open reﬂux-
ing segments of more than 5 cm of the treated GSV
compared with patients treated with stripping during the
5-year follow-up. The difference was not statistically
Fig 3. Legs without recurrent varicose veins. CI, Conﬁdence
interval; EVLA, endovenous laser ablation.
Fig 2. Legs without open reﬂuxing great saphenous vein (GSV)
segments. CI, Conﬁdence interval; EVLA, endovenous laser
ablation.
Table II. Comparison of cumulative recurrence rates
and source of reﬂux in patients 5 years after treatment
with surgery or EVLA
n ¼ legs
Surgery
(n ¼ 68),
No. (%)
EVLA
(n ¼ 69),
No. (%) P
Clinical recurrence 24 (35) 25 (36) .9
Technical failure 2 (3) 3 (4) .66
Reﬂux into the GSV 2 (8) 3 (12) .66
Reﬂux into the AAGSV 3 (13) 6 (24) .31
Reﬂux in the groin 1 (4) 2 (8) .57
Reﬂux in thigh perforators 8 (33) 5 (20) .37
Reﬂux in lower leg perforators 1 (4) 4 (16) .18
AAGSV, Anterolateral accessory great saphenous vein; EVLA, endovenous
laser ablation; GSV, great saphenous vein.
Fig 4. Legs without reoperations. CI, Conﬁdence interval; EVLA,
endovenous laser ablation.
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The failure rate is higher than in other reports, perhaps
because of the difference in criteria for failure or recanaliza-
tion. Our study could not conﬁrm the ﬁndings in a meta-
analysis by Renate van den Boss and coworkers, in which
duplex veriﬁed incompetence in the GSV was found more
frequently 5 years after surgery compared with EVLA.10
One explanation for this discrepancy may be that both
surgeons in the present study were highly experienced
with regard to surgical stripping.11 Recanalization after
endovenous treatment is well described, and failure to strip
the GSV when it snaps is also a frequent occurrence. The
longer-term clinical impact of recanalized segments of the
GSV is unknown, however. In the short term, recanalization
of the GSV after EVLA seems to have no importance.12 In
the present study, recanalization was not associated with
increased clinical recurrence nor did it seem to inﬂuence
VCSS or QOL. However, the sample size is too small to
allow deﬁnite conclusions regarding the clinical conse-
quences of recanalized segments of the GSV.
The clinical recurrence rate of varicose veins was high in
both groups with no difference between the groups. A high
recurrence rate is well described in other studies where
presence of recurrence is carefully sought for, and it maywell reach more than 60% of legs after 11 years.13-15 The
pattern of reﬂux in legs, which developed recurrent varicose
veins in our study, was not signiﬁcantly different between
the groups. A previous ﬁnding of increased neovasculariza-
tion in the groin after surgery could not be conﬁrmed in
the present study; however, such changes were only sought
in legs with recurrent varicose veins.2 Still, reﬂux in thigh
perforators was more frequently associated with clinical
recurrence in the surgery group, whereas reﬂux into the
AAGSV was seen more often in the EVLA group, although
patients with primary reﬂux in the AAGSV had been
excluded from the study. However, the differences were
not statistically signiﬁcant, perhaps because of a small
sample size.
There was no difference between the groups regarding
number of reoperations for recurrent varicose veins. Our
rate of reoperations is somewhat higher than the 10% reop-
erations after stripping during 11-year follow-up in a previous
study.13 The decision to re-treat might have been inﬂuenced
by the fact that the patients were seen regularly in a trial and
that re-treatment with foam sclerotherapy is easy. Both treat-
ments signiﬁcantly improved VCSS and QOL as reﬂected
by signiﬁcant improvements in AVVSS and in several
domains of SF-36 with no signiﬁcant differences in the
outcomes between the groups. The improvements persisted
Fig 5. VCSS from baseline to 5 years’ follow-up. CI, Conﬁdence
interval; EVLA, endovenous laser ablation; VCSS, Venous Clinical
Severity Score.
Fig 6. AVVSS from baseline to 5 years’ follow-up. AVVSS,
Aberdeen Varicose Vein Severity Score; CI, conﬁdence interval;
EVLA, endovenous laser ablation.
Table III. Medical Outcomes Study Short Form (SF-36)
health-related quality of life (QOL) score
SF-36 domain Time, years
EVLA Surgery
Mean P Mean P
Bodily pain 0 76.6 77.1
1 86.8 .0028 90.8 .0078
3 81.8 .1765 91.1 .1560
5 88.1 .0041 89.6 .1473
General health 0 65 67.7
1 64.7 .4120 69.7 .2844
3 62.3 .1576 68 .5352
5 62 .0642 68.6 .7845
Mental health 0 79.3 83.3
1 86.8 .0001 91 .0050
3 81.1 .2018 94.2 .0308
5 89.3 .0046 88.4 .3348
Physical function 0 85.8 86.6
1 93.3 .0005 92.2 .0008
3 90.7 .4233 92.2 .1938
5 89 .8053 91 .1676
Role-emotional 0 88.1 91.8
1 91.8 .5459 95.7 .2980
3 88.8 .3942 95.6 .5392
5 92.5 .7728 94.7 .4552
Role-physical 0 87 89.3
1 90.8 .3924 91.5 .7952
3 85.8 .3673 91.4 .3711
5 88.4 .6150 90.1 .1937
Social function 0 90.4 95.3
1 95.7 .0061 97.8 .4882
3 94.2 .0928 97.4 .7366
5 95.8 .0277 97.4 .9068
Vitality 0 69 73.1
1 74.7 .0301 81.7 .0186
3 72.3 .1749 81.9 .2663
5 79.5 .0007 84.2 .0274
MCS 0 52.7 55.6
1 55.5 <.0001 58.5 <.0001
3 53.5 <.0001 59.1 <.0001
5 57.3 <.0001 57.8 <.0001
PCS 0 50.7 50.7
1 52.6 <.0001 53 <.0001
3 51.3 <.0001 52.3 <.0001
5 51.1 <.0001 52.5 <.0001
EVLA, Endovenous laser ablation; MCS, mental component summary;
PCS, physical component summary.
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EVLA are efﬁcient treatments with long-term beneﬁcial
effects in patients with GSV varicose veins.16-19
One limitation of the present study is the fact that treat-
ments and assessments were not blinded. However, blinding
of the patient is not possible, whereas blinding of the
observer is technically possible but difﬁcult. It should be
noted, however, that during the long-term follow-up assess-
ments, the observer (nurse and surgeon) would have no
information of the primary procedure and in the vast
majority of cases, no recollection of it. Our results may not
apply to patients with post-thrombotic varicosity or to those
with incompetent accessory veins, deep veins, or small saphe-
nous veins since such patients were excluded from the study.
With the availability of two randomized trials with
follow-up to 5 years, showing no difference between
EVLA and surgery, in addition to several observational
studies, any skepticism toward EVLA as a relevant alterna-
tive treatment for GSV varicose veins becomes irrelevant.
However, because patients and surgeons differ, the choice
of treatment should be tailored to each individual patient,
taking into account anatomy as well as the patient and
surgeon preferences.AUTHOR CONTRIBUTIONS
Conception and design: LR, BE, LB
Analysis and interpretation: LR, ML, AB
Data collection: ML
Writing the article: LR, AB
Critical revision of the article: LR, ML, LB, BE, AB
Final approval of the article: LR, ML, LB, BE, AB
Statistical analysis: AB, ML
Obtained funding: LR
Overall responsibility: LR
REFERENCES
1. Murad MH, Coto-Yglesias F, Zumaeta-Garcia M, Elamin MB,
Duggirala MK, Erwin PJ, et al. A systematic review and meta-analysis of
JOURNAL OF VASCULAR SURGERY
426 Raffetto August 2013the treatments of varicose veins. J Vasc Surg 2011;53(5 Suppl):
49S-65S.
2. Disselhoff BC, der Kinderen DJ, Kelder JC, Moll FL. Five-year results
of a randomized clinical trial comparing endovenous laser ablation with
cryostripping for great saphenous varicose veins. Br J Surg 2011;98:
1107-11.
3. Rasmussen LH, Bjoern L, Lawaetz M, Blemings A, Lawaetz B,
Eklof B. Randomized trial comparing endovenous laser ablation of the
great saphenous vein with high ligation and stripping in patients with
varicose veins: short-term results. J Vasc Surg 2007;46:308-15.
4. Rasmussen LH, Bjoern L, Lawaetz M, Lawaetz B, Blemings A,
Eklof B. Randomised clinical trial comparing endovenous laser ablation
with stripping of the great saphenous vein: clinical outcome and
recurrence after 2 years. Eur J Vasc Endovasc Surg 2010;39:630-5.
5. Rutherford RB, Padberg FT Jr, Comerota AJ, Kistner RL,
Meissner MH, Moneta GL. Venous severity scoring: an adjunct to
venous outcome assessment. J Vasc Surg 2000;31:1307-12.
6. Garratt AM, Macdonald LM, Ruta DA, Russell IT, Buckingham JK,
Krukowski ZH. Towards measurement of outcome for patients with
varicose veins. Qual Health Care 1993;2:5-10.
7. Smith JJ, Garratt AM, Guest M, Greenhalgh RM, Davies AH. Evalu-
ating and improving health-related quality of life in patients with
varicose veins. J Vasc Surg 1999;30:710-9.
8. Perrin MR, Guex JJ, Ruckley CV, dePalma RG, Royle JP, Eklof B,
et al. Recurrent varices after surgery (REVAS), a consensus document.
REVAS group. Cardiovasc Surg 2000;8:233-45.
9. Stonebridge PA, Chalmers N, Beggs I, Bradbury AW, Ruckley CV.
Recurrent varicose veins: a varicographic analysis leading to a new
practical classiﬁcation. Br J Surg 1995;82:60-2.
10. van den Bos R, Arends L, Kockaert M, Neumann M, Nijsten T.
Endovenous therapies of lower extremity varicosities: a meta-analysis.
J Vasc Surg 2009;49:230-9.
11. Christenson JT, Gueddi S, Gemayel G, Bounameaux H. Prospective
randomized trial comparing endovenous laser ablation and surgery fortreatment of primary great saphenous varicose veins with a 2-year
follow-up. J Vasc Surg 2010;52:1234-41.
12. Theivacumar NS, Dellagrammaticas D, Darwood RJ, Mavor AI,
Gough MJ. Fate of the great saphenous vein following endovenous
laser ablation: does re-canalisation mean recurrence? Eur J Vasc
Endovasc Surg 2008;36:211-5.
13. Winterborn RJ, Foy C, Earnshaw JJ. Causes of varicose vein recur-
rence: late results of a randomized controlled trial of stripping the long
saphenous vein. J Vasc Surg 2004;40:634-9.
14. Kostas T, Ioannou CV, Touloupakis E, Daskalaki E, Giannoukas AD,
Tsetis D, et al. Recurrent varicose veins after surgery: a new appraisal of
a common and complex problem in vascular surgery. Eur J Vasc
Endovasc Surg 2004;27:275-82.
15. van Rij AM, Jiang P, Solomon C, Christie RA, Hill GB. Recurrence
after varicose vein surgery: a prospective long-term clinical study with
duplex ultrasound scanning and air plethysmography. J Vasc Surg
2003;38:935-43.
16. Sam RC, MacKenzie RK, Paisley AM, Ruckley CV, Bradbury AW. The
effect of superﬁcial venous surgery on generic health-related quality of
life. Eur J Vasc Endovasc Surg 2004;28:253-6.
17. Durkin MT, Turton EP, Wijesinghe LD, Scott DJ, Berridge DC. Long
saphenous vein stripping and quality of lifeea randomized trial. Eur J
Vasc Endovasc Surg 2001;21:545-9.
18. Michaels JA, Brazier JE, Campbell WB, MacIntyre JB, Palfreyman SJ,
Ratcliffe J. Randomized clinical trial comparing surgery with conser-
vative treatment for uncomplicated varicose veins. Br J Surg 2006;93:
175-81.
19. MacKenzie RK, Paisley A, Allan PL, Lee AJ, Ruckley CV,
Bradbury AW. The effect of long saphenous vein stripping on quality of
life. J Vasc Surg 2002;35:1197-203.Submitted Oct 11, 2012; accepted Dec 13, 2012.INVITED COMMENTARYJoseph D. Raffetto, MD, West Roxbury, MassIn this study, Rasmussen et al provide a 5-year follow-up of the
original randomized trial in which endovenous ablation was
compared with ligation and stripping of the great saphenous vein
in symptomatic patients with varicose veins that was published after
2 years of follow-up.1 The importance of long-term data demon-
strating durability and patient satisfaction after venous surgery is
imperative and was previously demonstrated by Merchant et al2 in
a multicenter prospective registry.
For many years, it has been presumed that endovenous abla-
tive techniques should be the primary treatment modality for the
reﬂuxing great saphenous vein and completely replace ligation
and stripping. This contention was speculative and without scien-
tiﬁc evidence. A small randomized trial by Lurie et al3 in which
endovenous radiofrequency ablation was compared with surgical
ligation and stripping demonstrated that at 2 years of follow-up,
in addition to similar treatment success and reduction in clinical
severity, the endovenous ablation group had signiﬁcantly reduced
pain as a quality-of-life dimension compared with surgery that per-
sisted up to 2 years.
Similar to the Lurie trial, the uniqueness of this study,
however, is that it compares a well-validated surgical techniqued
ligation and strippingdwith a relatively new treatment modality
encompassing endovenous laser ablation, with important primary
and secondary end points that mattered not only to the clinician
but also to the patient and over a long period of post-treatment
duration. Rasmussen et al found that both therapies were effective
and had no differences in recurrent reﬂuxing great saphenous vein,
recurrent varicose veins, clinical severity, and quality-of-life analysis.
The strength in any study evaluating long-term results is the
sample size in each group studied and the actual number of evaluablepatients at each year interval, and in this study, at the 5-year follow-
up. In addition to patient recruitment, understandably not all
patients will be available to evaluate, and in this study, the authors
recognize these limitations. However, this should not take away
from the signiﬁcance of this well-designed study, with well-
matched groups and relevant end points that are critically important
in clinical practice for physician caring for patients with venous
disease. Although our conﬁdence in treating patients with varicose
veins with less invasive modalities will increase, there is a barrage of
other modalities that have not been studied in a carefully designed
randomized trial that await bothprofessional and clinical acceptance.
I believe the study by Rasmussen et al has set the framework for
further work in this important ﬁeld, that will answer which treat-
ments, which outcomes, and what follow-up is necessary in deter-
mining best treatment practices for patients with varicose veins.REFERENCES
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